Nucleic acids encoding mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens
The present invention relates to nucleic acids encoding mosaic clade M HIV-1 Env polypeptides and to compositions and vectors comprising same. The nucleic acids of the invention are suitable for use in inducing an immune response to HIV-1 in a human.
1. An isolated and purified nucleic acid comprising a nucleotide sequence encoding a mosaic clade M human immunodeficiency virus type 1 (HIV-1) Env polypeptide comprising an amino acid sequence selected from the group consisting of M_mos_Env — 3 — 1 (SEQ ID NO:177), M_mos_Env — 3 — 2 (SEQ ID NO:178) and M_mos_Env — 3 — 3 (SEQ ID NO:179).
2. The nucleic acid according to claim 1 wherein said polypeptide comprises the amino acid of SEQ ID NO:177.
3. The nucleic acid according to claim 1 wherein said polypeptide comprises the amino acid of SEQ ID NO:178.
4. The nucleic acid according to claim 1 wherein said polypeptide comprises the amino acid of SEQ ID NO:179.
5. A composition comprising the nucleic acid according to claim 1 and a carrier.
6. A construct comprising the nucleic acid according to claim 1 and a vector.
7. The construct according to claim 6 wherein said nucleic acid is present in said vector operably liked to a promoter.
8. A method of inducing an immune response against HIV-1 in a host comprising administering to said host an amount of the nucleic acid according to claim 7 sufficient to induce said response.
9. A trivalent composition comprising nucleotide sequences encoding M_mos_Env — 3 — 1 (SEQ ID NO:177), M_mos_Env — 3 — 2 (SEQ ID NO:178) and M_mos_Env — 3 — 3 (SEQ ID NO:179).
10. The construct according to claim 6 wherein said vector is a viral vector.
11. The construct according to claim 10 wherein said viral vector is an adenoviral vector, an adeno-associated virus vector, a pox virus vector, an enteric virus vector, a Venezuelean Equine Encephalitis Virus vector, a Semliki Forest Virus vector or a Tobacco Mosaic Virus vector.
12. The construct according to claim 7 wherein said promoter is a CMV promoter.
13. The composition of claim 9 further comprising an adjuvant.
14. A method of inducing an immune response against HIV-1 in a host comprising administering to said host the composition according to claim 9 in an amount sufficient to induce said response.
15. The method according to claim 14 wherein each nucleic acid is operably linked to a promoter and is present in a vector.
16. The method according to claim 15 wherein said vector is a viral vector.
17. The method according to claim 16 wherein said viral vector is an adenoviral vector, an adeno-associated virus vector, a pox virus vector, an enteric virus vector, a Venezuelean Equine Encephalitis Virus vector, a Semliki Forest Virus vector or a Tobacco Mosaic Virus vector.
18. The method according to claim 15 wherein said promoter is a CMV promoter.